CA
SWTX

Continuum Advisory’s SpringWorks Therapeutics SWTX Stock Holding History

Continuum Advisory’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-63
Closed -$2.78K – 1430
2025
Q1 		$2.78K Hold
63
– – ﹤0.01% 1248
2024
Q4 		$2.28K Sell
63
-20
-24% -$699 ﹤0.01% 1373
2024
Q3 		$3.03K Sell
83
-22
-21% -$822 ﹤0.01% 1297
2024
Q2 		$3.96K Buy
105
+8
+8% +$337 ﹤0.01% 1130
2024
Q1 		$4.17K Buy
+97
New +$4.49K ﹤0.01% 1100

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Continuum Advisory's SWTX Position: Q2 2025 in Review

Continuum Advisory sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 63 shares — an estimated $2.78K sold.

Continuum Advisory first reported a position in SWTX in Q1 2024 and held it in 5 quarters. The position peaked at $4.17K in Q1 2024. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Continuum Advisory reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 63 SpringWorks Therapeutics shares in Q2 2025, an estimated $2.78K.
  • Continuum Advisory first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's SpringWorks Therapeutics position peaked at $4.17K in Q1 2024.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.